| Literature DB >> 34493867 |
Tongwu Zhang1, Philippe Joubert2, Naser Ansari-Pour3, Wei Zhao1, Phuc H Hoang1, Rachel Lokanga4, Aaron L Moye5, Jennifer Rosenbaum6, Abel Gonzalez-Perez7, Francisco Martínez-Jiménez7, Andrea Castro8, Lucia Anna Muscarella9, Paul Hofman10, Dario Consonni11, Angela C Pesatori11,12, Michael Kebede1, Mengying Li1, Bonnie E Gould Rothberg13,14, Iliana Peneva15,16, Matthew B Schabath17, Maria Luana Poeta18, Manuela Costantini19, Daniela Hirsch4, Kerstin Heselmeyer-Haddad4, Amy Hutchinson1,20, Mary Olanich1,20, Scott M Lawrence1,20, Petra Lenz1,20, Maire Duggan21, Praphulla M S Bhawsar1, Jian Sang1, Jung Kim1, Laura Mendoza1, Natalie Saini22, Leszek J Klimczak23, S M Ashiqul Islam24, Burcak Otlu24, Azhar Khandekar24, Nathan Cole1,20, Douglas R Stewart1, Jiyeon Choi1, Kevin M Brown1, Neil E Caporaso1, Samuel H Wilson22, Yves Pommier25, Qing Lan1, Nathaniel Rothman1, Jonas S Almeida1, Hannah Carter8, Thomas Ried4, Carla F Kim5,26, Nuria Lopez-Bigas7,27, Montserrat Garcia-Closas1, Jianxin Shi1, Yohan Bossé2,28, Bin Zhu1, Dmitry A Gordenin22, Ludmil B Alexandrov24, Stephen J Chanock1, David C Wedge3,29, Maria Teresa Landi30.
Abstract
Lung cancer in never smokers (LCINS) is a common cause of cancer mortality but its genomic landscape is poorly characterized. Here high-coverage whole-genome sequencing of 232 LCINS showed 3 subtypes defined by copy number aberrations. The dominant subtype (piano), which is rare in lung cancer in smokers, features somatic UBA1 mutations, germline AR variants and stem cell-like properties, including low mutational burden, high intratumor heterogeneity, long telomeres, frequent KRAS mutations and slow growth, as suggested by the occurrence of cancer drivers' progenitor cells many years before tumor diagnosis. The other subtypes are characterized by specific amplifications and EGFR mutations (mezzo-forte) and whole-genome doubling (forte). No strong tobacco smoking signatures were detected, even in cases with exposure to secondhand tobacco smoke. Genes within the receptor tyrosine kinase-Ras pathway had distinct impacts on survival; five genomic alterations independently doubled mortality. These findings create avenues for personalized treatment in LCINS.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34493867 PMCID: PMC8432745 DOI: 10.1038/s41588-021-00920-0
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330